[go: up one dir, main page]

CY1123405T1 - MAMMALIAN CELLS EXPRESSING CYTOmegalovirus Antigen - Google Patents

MAMMALIAN CELLS EXPRESSING CYTOmegalovirus Antigen

Info

Publication number
CY1123405T1
CY1123405T1 CY20201100546T CY201100546T CY1123405T1 CY 1123405 T1 CY1123405 T1 CY 1123405T1 CY 20201100546 T CY20201100546 T CY 20201100546T CY 201100546 T CY201100546 T CY 201100546T CY 1123405 T1 CY1123405 T1 CY 1123405T1
Authority
CY
Cyprus
Prior art keywords
cells expressing
mammalian cells
cytomegalovirus antigen
expressing cytomegalovirus
cmv
Prior art date
Application number
CY20201100546T
Other languages
Greek (el)
Inventor
Andrea Carfi
Claudio CIFERRI
Irmgard HOFMANN
Holger Laux
Anders Lilja
Yingxia Wen
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1123405T1 publication Critical patent/CY1123405T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η εφεύρεση αυτή αφορά σε πρωτεΐνες κυτταρομεγαλοϊού (CMV) κατάλληλες για χρήσεις εμβολίου. Παρέχονται στο παρόν κύτταρα θηλαστικού ξενιστές, συγκεκριμένα CHO κύτταρα, στα οποία οι αλληλουχίες που κωδικοποιούν πρωτεΐνες CMV gH, gL, pUL128, pUL130, pUL131 (ή θραύσμα σχηματισμού συμπλόκου αυτών) είναι σταθερά ενσωματωμένες εντός του γονιδιώματος.This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, specifically CHO cells, in which sequences encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.

CY20201100546T 2014-10-31 2020-06-16 MAMMALIAN CELLS EXPRESSING CYTOmegalovirus Antigen CY1123405T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14191385.5A EP3015475A1 (en) 2014-10-31 2014-10-31 Mammalian cells expressing cytomegalovirus antigens
PCT/IB2015/058349 WO2016067239A1 (en) 2014-10-31 2015-10-29 Mammalian cells expressing cytomegalovirus antigens

Publications (1)

Publication Number Publication Date
CY1123405T1 true CY1123405T1 (en) 2021-12-31

Family

ID=51844603

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100546T CY1123405T1 (en) 2014-10-31 2020-06-16 MAMMALIAN CELLS EXPRESSING CYTOmegalovirus Antigen

Country Status (19)

Country Link
US (1) US10414802B2 (en)
EP (2) EP3015475A1 (en)
JP (1) JP6688297B2 (en)
CN (1) CN107075486B (en)
AR (1) AR102464A1 (en)
BE (3) BE1023364B1 (en)
BR (1) BR112017008827A2 (en)
CA (1) CA2964859C (en)
CY (1) CY1123405T1 (en)
DK (1) DK3212660T3 (en)
ES (1) ES2799735T3 (en)
HR (1) HRP20200932T1 (en)
HU (1) HUE049356T2 (en)
LT (1) LT3212660T (en)
MX (1) MX387400B (en)
PL (1) PL3212660T3 (en)
PT (1) PT3212660T (en)
SI (1) SI3212660T1 (en)
WO (1) WO2016067239A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005959A1 (en) 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3536776B1 (en) * 2014-04-29 2023-10-25 Novartis AG Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
CN107723276B (en) * 2017-11-02 2021-08-13 上海交通大学 A method and kit for the construction of a cell line that stably and highly expresses a target product
SG11202010821TA (en) 2018-05-04 2020-11-27 Spybiotech Ltd Vaccine composition
AU2019397719B2 (en) * 2018-12-10 2023-11-09 Km Biologics Co., Ltd. Vaccine for preventing or treating congenital infection with cytomegalovirus
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
AU2021392077A1 (en) * 2020-12-02 2023-07-13 Seqirus Inc. Multicistronic rna vaccines and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DK0452484T3 (en) 1989-11-06 1996-10-14 Cell Genesys Inc Production of proteins by homologous recombination
US5589392A (en) 1991-01-14 1996-12-31 Stratagene Nucleic acid construct encoding a nuclear transport peptide operatively linked to an inducible promoter
EP2037959B1 (en) 2006-06-07 2016-01-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
JP2013544504A (en) * 2010-10-11 2013-12-19 ノバルティス アーゲー Antigen delivery platform
WO2014005959A1 (en) 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
EP2935319B1 (en) 2012-12-18 2019-04-24 Novartis AG Production of therapeutic proteins in genetically modified mammalian cells
KR102288857B1 (en) 2013-12-20 2021-08-11 노파르티스 아게 Novel eukaryotic cells and methods for recombinantly expressing a product of interest
SG11201604218RA (en) 2013-12-20 2016-07-28 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
WO2015165480A1 (en) * 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
EP3536776B1 (en) 2014-04-29 2023-10-25 Novartis AG Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest

Also Published As

Publication number Publication date
EP3212660A1 (en) 2017-09-06
BE1023840B1 (en) 2017-08-10
MX387400B (en) 2025-03-18
US20170362278A1 (en) 2017-12-21
EP3212660B1 (en) 2020-03-25
BR112017008827A2 (en) 2018-03-27
EP3015475A1 (en) 2016-05-04
CN107075486A (en) 2017-08-18
US10414802B2 (en) 2019-09-17
CA2964859C (en) 2023-04-04
CA2964859A1 (en) 2016-05-06
BE1023841A1 (en) 2017-08-09
HUE049356T2 (en) 2020-09-28
AR102464A1 (en) 2017-03-01
BE1023840A1 (en) 2017-08-09
JP2017534283A (en) 2017-11-24
MX2017005661A (en) 2017-06-26
LT3212660T (en) 2020-07-10
BE1023364B1 (en) 2017-02-20
BE1023364A1 (en) 2017-02-20
SI3212660T1 (en) 2020-07-31
WO2016067239A1 (en) 2016-05-06
JP6688297B2 (en) 2020-04-28
PL3212660T3 (en) 2020-10-05
PT3212660T (en) 2020-06-23
BE1023841B1 (en) 2017-08-10
DK3212660T3 (en) 2020-06-15
CN107075486B (en) 2021-06-22
ES2799735T3 (en) 2020-12-21
HRP20200932T1 (en) 2020-09-18

Similar Documents

Publication Publication Date Title
CY1123405T1 (en) MAMMALIAN CELLS EXPRESSING CYTOmegalovirus Antigen
CY1123598T1 (en) MACROCYCLIC PEPTIDES USED AS IMMUNE MODULATORS
CY1124176T1 (en) PREDICTING IMMUNOGENEITY OF T CELL EPITOPES
CY1124558T1 (en) PREDICTION OF T CELL SITE USABLE FOR VACCINATION
CY1121571T1 (en) Immunoregulators
CY1123563T1 (en) IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USING THEREOF
CY1124921T1 (en) METHODS FOR THE EXTRACTION AND PURIFICATION OF NON-DENATHERED PROTEINS
CY1121934T1 (en) ANTI-FCRN ANTIBODIES
IL263801B1 (en) Novel adeno-associated virus capsid proteins
PH12019501130A1 (en) Viral delivery of neoantigens
CL2017001584A1 (en) Antibiostatin antibodies, polypeptides containing variant fc regions, and methods of use
DK3348638T3 (en) METHOD OF CONVERTING GENOME SEQUENCE FROM GRAM-POSITIVE BACTERIA BY SPECIFICALLY CONVERTING NUCLEIC ACID BASE INTO THE INTENDED DNA SEQUENCE, AND MOLECULAR COMPLEX USED THEREFOR
EA201491837A1 (en) CHEMICAL ANTIGENOUS RECEPTORS AIMED AT ANTIGEN OF B-CELL MATURATION
CY1122214T1 (en) ANTIBODIES SPECIFIC TO TON FCRN
EA201690529A1 (en) METHODS OF MODIFICATION OF CELL-HOST
FR3023213B1 (en) LUMINOUS GLASS ASSEMBLY.
EA201692025A1 (en) DELIVERY OF PROTEINS, BASED ON BACTERIA
IL251571A0 (en) Lepidopteran-active cry1da1 amino acid sequence variant proteins
CY1120997T1 (en) UTI Fusion PROTEINS
MX378905B (en) PESTIVIRUS.
MX383506B (en) SWINE PARVOVIRUS.
DK3522905T3 (en) Immunogenic arginase peptides
DK3534936T3 (en) TOLEROGEN DNA VACCINE
IL265942A (en) Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
CY1124079T1 (en) EFFECTIVE SELECTIVITY OF RECOMBINANT PROTEINS